Merck & Co’s CEO Kenneth Frazier has said the pharma industry must take on the challenge of its poor public perception. In an interview with Yahoo Finance, Frazier defended the industry’s ...

Merck & Co’s strategy to spin off its older drugs and biosimilars into a new stand-alone business will be closely watched by other pharma companies considering the same move, analysts have said.

About aimed analytics aimed analytics, a pioneering company in AI-based data analytics, is enabling innovation in pharmaceutical ... collaboration with MSD/Merck for its Phase 2 study, OPTIMUS ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on. In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck ...

Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil ... and helped build a case against the pharmaceutical industry before judges ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical ... of our people and exacting analysis of our research processes.

(NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial hypertension ...

The stock currently trades near its 52-week low of $94.48, potentially presenting an opportunity as InvestingPro's Fair Value analysis ... Merck operates in a highly competitive pharmaceutical ...